Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No changes to company no reason to sell.
Its going to be a gapper
Most Excellent
SUNNYVALE, Calif., Oct. 25, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has received positive behavioural efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. The data shows superiority of MANF over GDNF, a neurotrophic factor currently in a Phase 2 clinical trial as a disease-modifying treatment for Parkinson's disease, by demonstrating that when MANF is delivered directly to the primary brain region associated with Parkinson's called the substantia nigra, MANF significantly reduced behavioural deficits in the model, whereas GDNF did not.
In Parkinson's disease, the nigro-striatal network (substantia nigra – striatum) is compromised due to the degeneration of dopaminergic neurons in the substantia nigra, which results in dopaminergic nerve terminal retraction from the striatum towards the substantia nigra. This leaves the striatum with inadequate dopamine levels, which in turn causes motor function deficits and other symptoms. Currently approved drugs that relieve symptoms focus on replacing the dopamine lost in the striatum; however, the symptom relief is temporary and the drugs typically lose their ability to abate symptoms roughly 7-10 years after the initiation of drug therapy. There are no approved therapies that focus on re-innervating the striatum by protecting dopaminergic neuron cell bodies in the substantia nigra while restoring dopaminergic innervation in the striatum.
In rat studies conducted by an independent academic laboratory contracted by Amarantus, 6-OHDA was injected directly into the striatum on one side of each rat's brain, causing their dopaminergic terminals to retract from the striatum towards the substantia nigra, and creating Parkinson's-like behavioural symptoms that were quantified by counting the number of times the rats turned in a circle in the same direction (behavioural deficits) in a given 120 minute period of time. MANF and GDNF were delivered directly into the substantia nigra of separate groups of rats 2 weeks following the administration of the 6-OHDA, in order to mimic as closely as possible in rats the treatment setting in humans where treatment would be administered after an extended timeframe following the initiation of dopaminergic nerve terminal retraction, each at the optimal dosing level of 10 micrograms. Four weeks following MANF treatment into the substantia nigra, behavioural deficits were reduced by ~43%, and six weeks following MANF treatment, behavioural deficits were reduced by ~53%; four weeks following GDNF treatment into the substantia nigra, behavioural deficits were reduced by ~16%, and six weeks following GDNF treatment, behavioural deficits actually increased by ~20%.
"The data obtained in this study provide clear evidence that MANF had a strong positive and restorative effect on the behaviour of animals in this pre-clinical Parkinson's disease study when delivered to the substantia nigra, whereas GDNF had no such effect," said John W. Commissiong PhD, Chief Scientist at Amarantus and former Head of the Neurotrophic Factors Group at the National Institutes of Health. "The localization of the drug treatment in this study is critical because, as Parkinson's disease progresses, dopaminergic nerve terminals typically retract from the striatum towards their cell bodies in the substantia nigra, resulting in the disruption of the basal ganglia network that is responsible for proper motor function. Translated, the longer you have Parkinson's disease, the less likely a neurotrophic factor will work when delivered to the striatum because there are fewer dopaminergic nerve terminals remaining to act on, and so neurotrophic factor drugs for later-stage patients will likely work best when delivered to the substantia nigra. No neurotrophic factor other than MANF has demonstrated efficacy in the neurorestoration behavioural 6-OHDA model of Parkinson's disease when delivered to the substantia nigra, so this makes today's result very significant. We are currently working to complete the analysis of histology data to confirm that it is in fact dopaminergic re-innervation of the striatum that is responsible for the results reported today. We expect to release the final results, including histology, to the public when the final data package is assembled in the next few months, and we will submit the final study report and manuscript for publication to a peer-reviewed scientific journal jointly with our academic collaborators and study sponsors at the same time. If the histology data confirm the mechanism underlying the behavioural results reported today, the biology causing today's result would represent a major scientific achievement that could lead to a medical breakthrough in treating Parkinson's disease."
Neurotrophic factors have been promising drug candidates for Parkinson's disease for over two decades because they have special biological properties that allow them to selectively protect certain neurons. Large biotechnology companies and leading academic investigators have conducted a number of clinical trials on GDNF in Parkinson's disease first initiated in 1996, at an estimated total cost of over $400M, where GDNF has shown promise as a disease-modifying treatment. However, technological limitations of delivering neurotrophic factors to the brain, limitations that Amarantus believes have been resolved by researchers in academia and industry, have delayed the translation of the underlying biology of neurotrophic factors into approved medicines. A unique drug such as MANF that potentially acts by re-innervating the striatum when delivered to the substantia nigra, combined with newly improved delivery technologies capable of getting MANF to the substantia nigra, could complement or replace drugs in development that may get to market ahead of MANF, especially in later-stage patients.
"Today's announcement is transformational for Amarantus from a scientific data standpoint," said Gerald E. Commissiong, President & CEO of Amarantus. "Despite the many clear scientific advantages we believe MANF possesses over GDNF, most notably impacting protein folding and modulating toxic calcium levels, the Company had previously been unable to point to a definitive behavioural animal model data to show improved benefit of MANF over GDNF in the Parkinson's disease indication. The data we now have validates the approach we have been taking over the last several years, and we believe that it will allow us to attract the interest of investment firms and potential partners who will be able to now characterize the substantial opportunity our technology represents. We believe that we are well positioned to leverage the MANF opportunity for Amarantus shareholders and Parkinson's patients because of the expansive intellectual property (IP) portfolio the Company owns, including composition of matter patents in the US and Europe, use patents worldwide and provisional delivery dosing patents that have been filed based on today's data, extending marketing exclusivity for MANF through 2031. This IP position may make MANF more attractive to a potential partner than other neurotrophic factors in development that do not have the same patent runway."
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.
alpha protein from immortalized cell lines
This is Exceptional
Buy now temp nervous nelly selling, news out in four days conference you know big buyers come in
Found this tidbit on another board. Regarding old shares.
"Just got off the phone with the SEC. I was informed that this has nothing to do with FINRA or Amerantus. This is entirely the transfer agent, VStock. The agent informed me that our shares should be updated on Friday, the 3rd business day from the effective date of the 28th. If our shares are not updated, she advised me ( so all of us old share holders ) to file a complaint with the SEC, enabling them to investigate. So, let's see what happens on Friday. If I were Gerald, I would be on the phone with the transfer agent because the last thing that i would think he wants is an investigation into this by the SEC at this crucial time for his company. Have a great day!" End quote.
Your stocks are safe remember SIPC
Mutual funds will want in at higher prices
THIS IS A $10.00 DOLLAR STOCK
Shorts will go chapter 7
$AMBS what a monster broke 10+ cents today closed with a gain of 40+%! Hands showed how strong they were, as MM's tried to slow it down to 7 cents, yet it closed at nearly the high of the day. This is not a make believe stock here. HUGE potential. Was under the radar, but not now, the buzz is getting crazy. 8K OUT / AMGEN as soon as it was revealed that AMGEN co founder bought shares, LOOK how STRONG it has been, and how fast it has moved, you cant IGNORE. This stock has NO LIMIT now. 1 call from the big boys and BINGO I found this from another trader written a month ago... BEFORE all this increedible new news.... nice read. Hot Biotech Stock- DRUG is FUNDED by MICHAEL J. FOX FOUNDATION for PARKINSON'S DISEASE. AMBS Released 2 Positive Drug Studies/Results and the stock is Poised to Run High! AMBS - Only Biotech Stock with a Potential Cure for Parkinson's Disease. This Stock is Way Undervalued. AMBS has only 227 mm shares Outstanding (float is around 70mm+). The market cap is only $20 mm and there's already been over $30mm invested in the research development of AMBS product candidates from biopharmaceutical companies, non-profit organizations, academic researchers and government agencies, including the National Institutes of Health. AMBS - Just announced a new Positive Study for its proprietary anti-apoptotic therapeutic protein known as MANF. According to a 2011 report by Visiongain, the market for Parkinson's disease drugs could grow to a value of $3.75 billion by 2015; AMBS is working on a candidate in the disease-modifying drug class which, if successful, could grab significant market share as well as substantially grow the overall Parkinsons drug market. There are currently no diagnostic tests available for Parkinsons disease, thus making AMBS test a first of its kind product capable of gaining a market leading position. AMBS - Owns the rights to a potential Cure for Parkinson's Disease. This news study out today tells us 3 very important things: 1. The study describes the critical role that MANF plays in protecting the Neuron's affected by Parkinson's Disease. 2. The study clearly shows that when MANF is removed from the Genome severe degeneration of the Neuron's occurs. 3. The study clearly shows that MANF plays a critical role in Membrane trafficking and Metabolic changes in the Neuron's affected by Parkinson's Disease. 4 Reasons Why AMBS - is the Hottest Undiscovered Biotech Stock play right now... 1. AMBS has a Parkinsons disease program, comprised of an early detection diagnostic blood test and a disease-modifying protein drug candidate. AMBS owns the rights to a potential cure for Parkinsonsa promising therapeutic protein known as MANF that prevents a type of cell death called apoptosis. That program is currently funded by a research grant from the Michael J. Fox Foundation for Parkinsons research... 2. AMBS also owns the license to a groundbreaking diagnostic platform called NuroPro for Parkinsons that allows neurologists to accurately diagnose and track the progression of Parkinsons disease in patients. The Companies believe that Amarantus NuroPro test for Parkinsons disease could be on market in certain regions as early as 2013. 3. Over $30million has already been invested in the research and development of AMBS product candidates from biopharmaceutical companies, non-profit organizations, academic researchers and government agencies, including the National Institutes of Health. 4. AMBS announced Drug Test Results the publication of positive, peer-reviewed efficacy data for MANF in an animal model of myocardial infarction. The results were published in The Journal of Biological Chemistry (JBC) by the Glembotski Lab at the San Diego State University's (SDSU) Department of Biology and the SDSU Heart Institute. The research paper entitled Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects the heart from Ischemic damage and is selectively secreted upon ER calcium depletion reports a ~44% reduction in infarct zone size in MANF-treated mice when compared with controls.
Anyone going to Drake hotel?[/b
On 8 November 2012, Amarantus BioScience, Inc. issued a press release indicating that data stemming from its research grant from the Michael J. Fox Foundation would be released to the public in December 2012. The Company has decided to withhold the release of the data until January 8th, 2013 at 1:40pm Pacific time, when the Company’s Chief Scientific Officer Dr. John W. Commissiong will present the data at the OneMedForum 2013 at the Sir Francis Drake Hotel in San Francisco, CA. The presentation will be made available online at http://onemedplace.com/forum/webcast/ . The cause for the delay is the Company is conferring with leading academics and collaborators to confirm various aspects of the data results in order to ensure complete accuracy and transparency. The Company believes confirmation of the results with leaders in the field prior to release to the public is in the best interests of its shareholders
Looks like lose shares are selling free shares.
Once all the financings were done, it appears to me that
many hundreds of thousands of shares were allowed to
trade freely in the market, thus they dumped their
shares to get "their commission".
I would buy on a regular basis and lower your
basis cost of this stock.
Once your cost basis is lower much lower,
then as Lithium demand show up again in the late fall,
of this year and into 2012 the shares will be up
significantly again and your cost is in profit.
Its Ugly and not nice, but its a startup and its a miner
so buy on the way down and double down on the way down.
It will rise again and you will be happy to have the shares.
Management are not rock stars, but they are swinging the bat
hard. Once the POSCO agreement hits, the stock should
radically go higher.
I just buy some every week, therefore I have a cost average.
Great way to get wealthy. Some day this stock will be either bought out or be $5.0 going to $50.
I'm making sure I have 1,000,000 one million shares.
Thats only 2300 in today's world.
One Million shares and well lets ramble.
Yes, I agree. I own some MMTE as well. Its 5billion shares are a cause of concern, but it can triple in value very easily and possibibly do a 10 banger. So can LIEG only its not a sub pennty stock.
I think LIEG is structured more like a Nasdaq Miner company.
Once it gets exposed to the investment community.
Thanks to adb2003 comments below. The news sequence is definately news of a company that has stong mangement and alignment to future growth for the shareholders. The recent share restructure with aquisition of the high quality Lithium concesions was worth on paper about 57million dollars. Wow. And now what else could happen next? Those concessions and associated partners are very happy to have been paid in cash and stock in this exciting company. What connetions will occur next are likley to be more large properties in the region. The credibility just jumped by
%100 for LIEG. And as you read below the listing on a new exchange, and the exciting news in the recent stock exchanges in the region will allow investors globally to access this company as a investment worldwide. This is better than being listed on the New York Stock exchange, since specaltive investors tend to look elsewhere for future investments that are un-discoverd by Wall-Street. This is a hidden gem of many magnitudes that will out perform its peers.
READ THIS: News summary - brief highlights from the LIEG acquisition of 60% controlling interest in Maricunga project. And HUGE partnership with one of the leading steel/lithium battery manufacturers on the planet!
Key point. This management team has a strong strategy, has planned clever synergistic acquisition's and has secured the distribution channels for its product. It is setting the stage for explosive growth. Work programs commencing - out to tender soon.
05/23 Li3 Energy Closes Strategic Maricunga Acquisition and Financing Transaction
With this controlling interest in the Maricunga property (ranked by SignumBOX as one of the top ten lithium projects in the world) and its other prospective strategic lithium and other mineral holdings, Li3 is now firmly focused on the acquisition and development of highly prospective lithium brine properties in the Americas.
05/09 Li3 Energy Signs MOU With One of the World's Largest Steel Manufacturers for Access to Lithium
POSCO is a diversified company, with operations in energy, chemicals and materials. POSCO is one of the largest steel manufacturers in the world with $56 billion in annual revenues and invests in numerous global resource development projects and has been actively evaluating and pursuing leading lithium projects globally.
The government of the Republic of South Korea, one of the world's leading lithium battery producing nations has mandated to invest $12.5 billion over the next ten years in lithium resource projects and deemed lithium a "strategic commodity."
03/01 Li3 Energy, Inc. has Signed a Binding Agreement to Acquire the Maricunga Lithium Project and has Begun the Process of Applying to List on the Toronto Stock Exchange
Regarding the POSCO agreement or (MOU) Memorandum of Understanding. Since I believe that the MOU is a solid agreement that means that the Korean 59billion Steel company can build a facility in Peru and or Korea to process the lithium carbonate, they would not go to this length to have a ceremony with all its meanings and pride associated by the Korean unless they were very very serious about acquiring access to these resources. Its going to happen in my opinion and when it does this company LIEG whether or not more dilution occurs which it will become a global supplier of Lithium to large markets.
It’s the best news on any lithium company that I have research in all of the Americas' including SQM. In fact it’s like LIEG is a baby SQM company, and with this agreement comes revenue and further capital investments that are larger than any stock capital raise, since POSCO can invest unlimited amounts to make the deal work. The recent stock price reduction is a gift to any new investors.
I'm buying shares for the remaining of this year all year.
The more you have on a average cost basis will reward you into the future as Lithium demand continues to soar.
As far as POSCO goes, Warren Buffet owns about 4.5 % of POSCO.
POSCO wants to own a significant percentage of LIEG.
It’s just a matter of time and this will command a price in the dollars not sub dollars.
Ok, very cool. The pump is primed. This is prime beef.
Big time.
It was way wrong what you did. Now your trying to belittle me.
Good look in life.
Its never a good idea to post what you think will happen near term to try to claim some sort of "GOD" "Value" that you know ahead of time information that you really have no idea.
It is sad that our society has become so temporary that we have people like the most recent poster on this board who claim they know something but know absolutely nothing, Nata, nothing at all.
And that this could have caused many hundreds of thousands of shares to Buy -- sounds like a lawsuit to me.
So keep you fricking mouth shut.
breezy1 LIEG .41
Li3 Energy Signs MOU With One of the World's Largest Steel Manufacturers for Access to Lithium
http://finance.yahoo.com/news/Li3-Energy-Signs-MOU-With-One-prnews-2855226321.html?x=0&.v=1
If you want a investment in the future of Automobile and Lithium this one is getting attention and based on my research should be trading in the 3-5 dollar level now.
Long term this could be in the realm of SQM a mining company in the same geographic region of the world that is conducive to large land based minerals.
Sociedad Quimica y Minera S.A. (NYSE: SQM ) is 56.98 a share right now on the New York. It started out in its early formation like LIEG.
Li3 Energy, Inc. (LIEG.OB)
One question you must ask yourself why is a 59billion congolmerate from South Korea, (and Korea makes 1/3 of the Lithiom-Ion Batteries), cheap labor you can certainly understand. Why then is a Multi National Corporation of 59billion in size even talking to little old LIEG. Why, they have land concesions closing very soon that allow a larger company like POSCO, (NYSE:PKX - News), a Republic of South Korea multinational global leader to get in the game of Lithium Raw materials from a Local connected company. Perfect combination.
POSCO is a diversified company, with operations in energy, chemicals and materials.
And an option to invest $25million by End of June at .27 cents a share approx.
So if a multi-national comes knocking on your door, what do think is going to happen next.
This company is getting a Grand-Dady of a Investor assisting in its growth.
Also not to mention LIEG has raised considerable capital recently Hard Cash that is buying up property that contains lithium.
Lithium is like Petroleum 100 years ago.
I bought about 40k shares and will be buying more. Closed Friday at .41 USD Cents.
Symbol: LIEG.
Li3 Energy Signs MOU With One of the World's Largest Steel Manufacturers for Access to Lithium
http://finance.yahoo.com/news/Li3-Energy-Signs-MOU-With-One-prnews-2855226321.html?x=0&.v=1
If you want a investment in the future of Automobile and Lithium this one is getting attention and based on my research should be trading in the 3-5 dollar level now.
Long term this could be in the realm of SQM a mining company in the same geographic region of the world that is conducive to large land based minerals.
Sociedad Quimica y Minera S.A. (NYSE: SQM ) is 56.98 a share right now on the New York. It started out in its early formation like LIEG.
Li3 Energy, Inc. (LIEG.OB)
One question you must ask yourself why is a 59billion congolmerate from South Korea, (and Korea makes 1/3 of the Lithiom-Ion Batteries), cheap labor you can certainly understand. Why then is a Multi National Corporation of 59billion in size even talking to little old LIEG. Why, they have land concesions closing very soon that allow a larger company like POSCO, (NYSE:PKX - News), a Republic of South Korea multinational global leader to get in the game of Lithium Raw materials from a Local connected company. Perfect combination.
POSCO is a diversified company, with operations in energy, chemicals and materials.
And an option to invest $25million by End of June at .27 cents a share approx.
So if a multi-national comes knocking on your door, what do think is going to happen next.
This company is getting a Grand-Dady of a Investor assisting in its growth.
Also not to mention LIEG has raised considerable capital recently Hard Cash that is buying up property that contains lithium.
Lithium is like Petroleum 100 years ago.
I bought about 40k shares and will be buying more. Closed Friday at .41 USD Cents.
Symbol: LIEG.
The Company is performing perfectly. You could not ask for a better set of circumstances. Low Price, Low volitility compared to its siblings, and huge... HUGE reserves. And Financing, and a small note, a 59 billion company in its pocket as a partner.